JP2008069159A5 - - Google Patents

Download PDF

Info

Publication number
JP2008069159A5
JP2008069159A5 JP2007243731A JP2007243731A JP2008069159A5 JP 2008069159 A5 JP2008069159 A5 JP 2008069159A5 JP 2007243731 A JP2007243731 A JP 2007243731A JP 2007243731 A JP2007243731 A JP 2007243731A JP 2008069159 A5 JP2008069159 A5 JP 2008069159A5
Authority
JP
Japan
Prior art keywords
ranolazine
plasma
use according
hours
methacrylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007243731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008069159A (ja
Filing date
Publication date
Priority claimed from US09/520,932 external-priority patent/US6479496B1/en
Application filed filed Critical
Publication of JP2008069159A publication Critical patent/JP2008069159A/ja
Publication of JP2008069159A5 publication Critical patent/JP2008069159A5/ja
Pending legal-status Critical Current

Links

JP2007243731A 2000-03-08 2007-09-20 持続放出ラノラジン製剤 Pending JP2008069159A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/520,932 US6479496B1 (en) 1998-09-10 2000-03-08 Methods for treating angina with ranolazine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001564746A Division JP4108980B2 (ja) 2000-03-08 2001-03-07 持続放出ラノラジン製剤

Publications (2)

Publication Number Publication Date
JP2008069159A JP2008069159A (ja) 2008-03-27
JP2008069159A5 true JP2008069159A5 (enExample) 2011-10-06

Family

ID=24074628

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001564746A Expired - Lifetime JP4108980B2 (ja) 2000-03-08 2001-03-07 持続放出ラノラジン製剤
JP2007243731A Pending JP2008069159A (ja) 2000-03-08 2007-09-20 持続放出ラノラジン製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001564746A Expired - Lifetime JP4108980B2 (ja) 2000-03-08 2001-03-07 持続放出ラノラジン製剤

Country Status (16)

Country Link
US (1) US6479496B1 (enExample)
EP (1) EP1263439A2 (enExample)
JP (2) JP4108980B2 (enExample)
CN (1) CN1323664C (enExample)
AU (3) AU2001240092B8 (enExample)
BR (1) BR0109091A (enExample)
CA (1) CA2402222C (enExample)
CZ (1) CZ20022996A3 (enExample)
HU (1) HUP0204409A3 (enExample)
IL (1) IL151575A0 (enExample)
MX (1) MXPA02008654A (enExample)
NO (1) NO20024270L (enExample)
NZ (1) NZ521292A (enExample)
PL (1) PL357273A1 (enExample)
RU (1) RU2002126615A (enExample)
WO (1) WO2001066093A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
WO2006074398A2 (en) * 2005-01-06 2006-07-13 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CN100455288C (zh) * 2006-06-26 2009-01-28 哈药集团制药总厂 一种盐酸雷诺嗪制剂配方
US20080031947A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. Orally dissolvable/disintegrable lyophilized dosage forms containing protected
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
EP2117508A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Intravenous solutions comprising ranolazine
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US7943620B2 (en) * 2007-03-07 2011-05-17 Concert Pharmaceuticals, Inc. Anti-anginal compounds
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
WO2008150565A2 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
BRPI0721741A2 (pt) * 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
CA2690379A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
NO3175985T3 (enExample) 2011-07-01 2018-04-28
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
EP4076398B1 (en) 2019-12-16 2026-02-18 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hf-pef)
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ATE218344T1 (de) * 1989-06-23 2002-06-15 Syntex Llc Ranolazin und verwandte piperazine zur behandlung von schockzuständen
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物

Similar Documents

Publication Publication Date Title
JP4108980B2 (ja) 持続放出ラノラジン製剤
JP3745621B2 (ja) 持続放出型ラノラジン製剤
JP2008069159A5 (enExample)
AU2001240092A1 (en) Sustained release ranolazine formulations
US20020052377A1 (en) Method for treating angina